Express Pharma

JANUARY 17, 2025

As environmental concerns continue to intensify, the pressure on the pharmaceutical industry to reduce its overall environmental impact, particularly in final dosage forms, is growing proportionately. Lonzas comprehensive sustainability approach spans the entire value chain, from raw material selection to end-of-life solutions.

Dosage 104

Dosage Pharmaceutical Manufacturing Packaging Drug Development 104

Express Pharma

MAY 10, 2023

However, this philosophy isn’t just relegated to guiding the practices of medical professionals and drug developers. It extends all the way down to the healthcare sector’s expectations for every component, instrument, and process orbiting the development and manufacture of medicine—especially parenteral drugs.

Packaging 97

Packaging Dosage Labelling Immunity 97

Pharmaceutical Technology

SEPTEMBER 8, 2022

Pharmaceutical solid dosage forms are the most popular in the pharmaceutical industry and are one of the most used drug delivery methods across patient groups. Growth of oral solid dosage contract manufacturing in the pharmaceutical industry.

Dosage 40

Dosage Packaging Documentation Pharmaceutical Companies 40

European Pharmaceutical Review

FEBRUARY 14, 2024

It is well understood that drug substance shelf life is extended when the cells are maintained in a cryo-preserved state at –20°C or below. Tablet dosage forms are feasible but run the risk of losing cell viability during compression and exposure to solvent during direct coat application to the tablet surface may result in viable cell loss.

Dosage 97

Dosage Packaging Labelling Compounding 97

Syner-G

SEPTEMBER 20, 2023

By: Mayuri Mutha, Senior Manager, CMC Development & Project Management Joseph Sclafani PhD, Director, CMC Development & Project Management Drug development is a complex, expensive, and multistage process which could take 10 to 15 years to bring a new molecule from discovery to commercialization.

Drug Development 59

Drug Development Documentation Dosage Packaging 59

European Pharmaceutical Review

JUNE 24, 2022

But what are the key potential changes and how could they impact drug developers and manufacturers? He noted that within the proposals, there is likely to be a differentiation in incentives for drug development in the orphan and unmet medical need areas. Key areas of potential legislative change. Future outlook.

Compounding 105

Compounding Drug Development Drug Pricing Dosage 105

Viseven

AUGUST 15, 2024

The traditional model of drug development and healthcare delivery is undergoing a seismic shift, with patient engagement emerging as a critical factor in achieving better health outcomes and driving innovation. This change is further driven by major regulatory bodies emphasizing Patient-Focused Drug Development (PFDD).

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication Drug Development 52